Effects of novel Fufang Biejia Ruangan Tablets with sheep placenta as substitute for Hominis Placenta on CCl

Author: Baode SHEN ¹ ; Yuan LIU ¹ ; Chengying SHEN ¹ ; Xiao LIU ¹ ; Hailong YUAN ¹ ; Li DENG ² ; Yinchao LI ² ; Ruisheng LI ³ ; Li DENG ⁴
Author Information

1. Department of Pharmacy, Air Force Medical Center, PLA
2. College of Pharmaceutical Sciences, Zhengzhou University
3. Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese, PLA General Hospital
4. School of Chemistry, Biology and Material Science, East China University of Technology
Publication Type:Journal Article
Keywords: Fufang Biejia Ruangan Tablet; Hominis Placenta; liver fibrosis; sheep placenta; substitute; TGF-β1/Smad signaling pathway
From: Chinese Herbal Medicines 2022;14(1):104-110
CountryChina
Language:Chinese
Abstract: Objective: Fufang Biejia Ruangan Tablet (FBRT) is widely used for the treatment of liver fibrosis. However, Hominis Placenta (HP), as an important adjuvant of FBRT, has been restricted for medicinal using due to the limited availability, ethical controversy and safety issues. The present study aimed to investigate the therapeutic effects of novel FBRT (N-FBRT) with sheep placenta (SP) as substitute for HP on liver fibrosis and explore its possible mechanisms. Different dosages of SP in N-FBRT were also evaluated. Methods: Rats were subcutaneously injected with CCl